Medicare Enrolled
Dr. Sven De Vos, MD
Hematology & Oncology · Los Angeles, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. De Vos from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. De Vos?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. De Vos
Dr. Sven De Vos is a hematology & oncology specialist in Los Angeles, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. De Vos performed 10,482 Medicare services across 1,821 unique beneficiaries.
Between the years covered by Open Payments, Dr. De Vos received a total of $27,026 from 16 pharmaceutical and/or device companies across 36 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. De Vos is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 28% volume in CA
$27,026 industry payments
Medicare Practice Summary
Medicare Utilization ↗10,482
Medicare services
Top 28% in CA for hematology & oncology
1,821
Unique beneficiaries
$30
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~552 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | 4,340 | $38 | $172 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
710 | $0 | $5 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
622 | $8 | $58 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
603 | $10 | $67 |
| Lactate dehydrogenase (LDH) level test A blood test that measures the amount of lactate dehydrogenase, an enzyme found in many body tissues. It helps assess tissue damage or disease. |
495 | $6 | $45 |
| Sed rate test (inflammation marker) This automated test measures how quickly red blood cells settle in a tube to detect inflammation in the body. |
433 | $3 | $20 |
| Beta-2 microglobulin level test A blood test that measures the level of beta-2 microglobulin, a protein produced by cells in the body. |
427 | $16 | $103 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
370 | $109 | $858 |
| Anti-nausea injection (Aloxi/palonosetron) | 360 | $1 | $95 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
302 | $66 | $508 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
254 | $1 | $10 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
192 | $67 | $470 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
140 | $14 | $245 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
124 | $27 | $475 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
123 | $96 | $680 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
122 | $1 | $10 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
101 | $120 | $1,045 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
98 | $18 | $150 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
96 | $26 | $550 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
87 | $58 | $383 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
70 | $1 | $15 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
57 | $158 | $960 |
| Immunoglobulin level test A blood test that measures the level of gammaglobulins, which are immune system proteins. |
49 | $9 | $65 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
44 | $12 | $121 |
| Uric acid level test A blood test that measures the level of uric acid in your body. Uric acid is a waste product formed when the body breaks down purines. |
40 | $4 | $34 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
39 | $59 | $620 |
| Hospital discharge management, 30+ min This service covers the care provided by a physician or qualified healthcare professional on the day a patient is discharged from the hospital. It requires more than 30 minutes of total time spent on the day of discharge. |
32 | $90 | $499 |
| Phosphate level test A blood test that measures the amount of phosphate in your body. Phosphate is a mineral that helps keep bones and teeth strong. |
27 | $4 | $42 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
22 | $148 | $1,320 |
| Amylase enzyme level test A blood test that measures the amount of amylase, an enzyme produced by the pancreas and salivary glands, to help evaluate pancreatic health. |
20 | $6 | $42 |
| Lipase level test A blood test that measures the amount of lipase, a fat-digesting enzyme, in your body. |
19 | $6 | $51 |
| CA 19-9 tumor antigen test A blood test that measures the level of CA 19-9, a substance that can be found in the blood of some people with cancer. This quantitative analysis detects and measures the specific tumor antigen. |
18 | $20 | $154 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
17 | $8 | $25 |
| Magnesium level test A blood test to measure the amount of magnesium in your body. This helps check for magnesium deficiency or excess. |
16 | $7 | $49 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
13 | $43 | $354 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
7.4% high complexity
55.4% medium
37.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$27,026
Total received (2018-2024)
Avg $4,504/year across 6 years
Top 17% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
16
Companies
36
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$22,805 (84.4%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$3,493 (12.9%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$728 (2.7%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$158
2023
$1,906
2022
$361
2021
$2,083
2019
$827
2018
$21,691
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Genmab U.S., Inc.
$158
Top 3 companies account for 100.0% of 2024 payments
All-time payments by company (2018-2024) ›
Gilead Sciences, Inc.
$19,311
BeiGene USA, Inc.
$1,950
Bayer HealthCare Pharmaceuticals Inc.
$1,835
ADC Therapeutics America, Inc.
$1,543
F. Hoffmann-La Roche AG
$728
AstraZeneca Pharmaceuticals LP
$566
Novartis Pharmaceuticals Corporation
$227
Genmab U.S., Inc.
$158
Genentech, Inc.
$150
Genentech USA, Inc.
$149
Janssen Scientific Affairs, LLC
$138
Secura Bio, Inc.
$87
Celgene Corporation
$72
ABBVIE INC.
$53
Pharmacyclics LLC, an AbbVie Company
$49
AbbVie, Inc.
$12
Top 3 companies account for 85.5% of all-time payments
Associated products mentioned in payments ›
Aliqopa · BRUKINSA · CALQUENCE · Columvi · Epkinly · FARYDAK · IMBRUVICA · KYMRIAH · Revlimid · VENCLEXTA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (84%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
354
Per 100K population
3.6
County median income
$87,760
Nearest hospital
RONALD REAGAN UCLA MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. De Vos is a mixed practice specialist, with above-average Medicare volume (top 28% in CA), with low-engagement industry engagement in the top 17% of CA peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. De Vos experienced with injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg?
Based on Medicare claims data, Dr. De Vos performed 4,340 injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. De Vos receive payments from pharmaceutical companies?
Yes. Dr. De Vos received a total of $27,026 from 16 companies across 36 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. De Vos's costs compare to other hematology & oncology specialists in Los Angeles?
Dr. De Vos's average Medicare payment per service is $30. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. De Vos) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Los Angeles
Browse hematology & oncology specialists in Los Angeles ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
Gilead Sciences, Inc. Payments to Doctors
See all physicians who received payments from Gilead Sciences, Inc.
By company
BeiGene USA, Inc. Payments to Doctors
See all physicians who received payments from BeiGene USA, Inc.
By company
Bayer HealthCare Pharmaceuticals Inc. Payments to Doctors
See all physicians who received payments from Bayer HealthCare Pharmaceuticals Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology